Replies to post #798878 on NorthWest Biotherapeutics Inc (NWBO)

[DrHigh]

I dont see how the AS increase they are asking for is enough to fund this construction, keeping lights on and covering the existing over allotment. Not adding up for me. They should have asked for a hike to 3Billion minimum. the stock is certainly goign to hit all time lows in Q1 2026. 200mm shares at 15 cents a share (and IMP will go lower) is only $30million. They will run out of $ and auth share capacity in no time.

[FeMike]

DD (you’re the real DD by the way, not danish dud) I agree with pretty much everything here but I don’t agree with the MHRA approval aspect.

I am confident MHRA can and will approve regardless of the manufacturing. I don’t guarantee it, but am confident nonetheless.

NICE is the issue, as that is the aspect of the process that considers cost of manufacturing. MHRA should be completely decoupled. Even if the cost is $10 million per dose, Northwest has manufacturing currently in place to produce it so MHRA can approve.

I think the approval delay is more related to NWBO intentionally stretching it out (and MHRA accommodating) because they all know NICE wont approve artisan.

[AllSheWrote]

Well thisPR just confirmed what I have been saying all alone.

The MHRA review isn’t “late.” It’s being driven by the CMC expansion the shift to Flaskworks and Grade C.

The PR confirmed nothing of the sort. Manufacturing has nothing to do with MHRA review.